Sector Alpha Week of 2026-08-05
20-quarter listed-company comparison

Pharma - Others Stocks in India

Pharma - Others: Unichem Laboratories Ltd owns the largest revenue base; JOJO Ltd has the fastest current growth.

01 · the index people search for

Nifty Pharma - Others Index — Constituents & Performance

The Pharma - Others companies below are the listed Indian Pharma - Others universe this page tracks — the same constituent set people search for as the Nifty Pharma - Others index. Every figure is equal-weighted across those companies, so one large constituent cannot set the reading. Each number carries its own as-of date.

02 · the sector itself · before any single company

How has Pharma - Others moved against NIFTY 500?

The line below covers up to 5.2 years and opens on the 5Y view; the buttons cut it shorter. Over the most recent two of them this sector is 70% ahead of NIFTY 500. Earnings across its companies fell 14% on average over the last four reported quarters. It has been ahead of NIFTY 500 on a rolling three-month view for 15 weeks running.

LEADER · ahead 15w✓Price up, without the fundamentals confirming4 of 9 companies ahead of NIFTY 500 by 5% or more over three months2 are 20% or more behind over a year while earnings grew 20% or more

RS ↑15w · 6/9 >200d (+0) · 4/9 lead (−3) · EPS 7/9↑

2005001000200020262025202420232022 2861333 TRAILING 12-MONTH EPS · 100 AT THE START0100218Sep 23Mar 24Sep 24Mar 25Sep 25Mar 26Sep 2023 · trailing 12-month earnings per share at 100, against 100 at the start · down 27.7% on a year ago · 5 reportingDec 2023 · trailing 12-month earnings per share at 107, against 100 at the start · down 100.0% on a year ago · 4 reportingMar 2024 · trailing 12-month earnings per share at 108, against 100 at the start · up 78.2% on a year ago · 5 reportingJun 2024 · trailing 12-month earnings per share at 125, against 100 at the start · down 100.0% on a year ago · 4 reportingSep 2024 · trailing 12-month earnings per share at 140, against 100 at the start · up 40.0% on a year ago · 5 reportingDec 2024 · trailing 12-month earnings per share at 112, against 100 at the start · down 11.0% on a year ago · 4 reportingMar 2025 · trailing 12-month earnings per share at 135, against 100 at the start · down 10.6% on a year ago · 5 reportingJun 2025 · trailing 12-month earnings per share at 104, against 100 at the start · down 48.8% on a year ago · 4 reportingSep 2025 · trailing 12-month earnings per share at 124, against 100 at the start · down 19.2% on a year ago · 5 reportingDec 2025 · trailing 12-month earnings per share at 198, against 100 at the start · down 28.3% on a year ago · 4 reportingMar 2026 · trailing 12-month earnings per share at 218, against 100 at the start · up 39.1% on a year ago · 4 reportingNot reported yet — earnings trail price by a quarter or two218 · Mar 26No earnings on file this far back — the price series reaches further than the filings doNO EARNINGS ON FILE
2005001000200020262025202420232022 2861333 TRAILING 12-MONTH EPS · 100 AT THE START0100218Mar 24Mar 25Mar 26Sep 2023 · trailing 12-month earnings per share at 100, against 100 at the start · down 27.7% on a year ago · 5 reportingDec 2023 · trailing 12-month earnings per share at 107, against 100 at the start · down 100.0% on a year ago · 4 reportingMar 2024 · trailing 12-month earnings per share at 108, against 100 at the start · up 78.2% on a year ago · 5 reportingJun 2024 · trailing 12-month earnings per share at 125, against 100 at the start · down 100.0% on a year ago · 4 reportingSep 2024 · trailing 12-month earnings per share at 140, against 100 at the start · up 40.0% on a year ago · 5 reportingDec 2024 · trailing 12-month earnings per share at 112, against 100 at the start · down 11.0% on a year ago · 4 reportingMar 2025 · trailing 12-month earnings per share at 135, against 100 at the start · down 10.6% on a year ago · 5 reportingJun 2025 · trailing 12-month earnings per share at 104, against 100 at the start · down 48.8% on a year ago · 4 reportingSep 2025 · trailing 12-month earnings per share at 124, against 100 at the start · down 19.2% on a year ago · 5 reportingDec 2025 · trailing 12-month earnings per share at 198, against 100 at the start · down 28.3% on a year ago · 4 reportingMar 2026 · trailing 12-month earnings per share at 218, against 100 at the start · up 39.1% on a year ago · 4 reportingNot reported yet — earnings trail price by a quarter or two218No earnings on file this far back — the price series reaches further than the filings doNO EARNINGS ON FILE
Pharma - Others, equal-weighted, based at 200 NIFTY 500, same base, same start trailing 12-month earnings per share rising falling

Both lines start at 200 in the same week, so the distance between them is the whole story: the sector line is an equal-weighted index of its 9 companies. The bars underneath are trailing 12-month earnings per share, one bar per reported quarter, each member rebased to 100 at the start and the sector taking the median — so a price line pulling away from flat bars is a re-rating, not earnings. A bar turns red when that figure is lower than the quarter before. Rules are fixed and applied identically everywhere on this site: ahead by 5% or more over three months, or behind by 20% or more over a year while earnings grew 20% or more. Hover any point to read both values and the gap. This is a description of what the numbers did, not advice.

03 · sector relative strength, before individual stocks

Is Pharma - Others outperforming NIFTY 500?

Pharma - Others has outperformed NIFTY 500 by 16.3% over the last 52 weeks. Over 13 weeks the gap is a lead of 16.2%. 8 of 10 covered companies currently beat NIFTY on Mansfield relative strength, so leadership inside the sector is selective. Shukra Pharmaceuticals Ltd is the strongest against the sector itself at +49.8%. Readings are as of 2026-07-19.

+16.2%Sector vs NIFTY 500 · 13 weeks
+16.3%Sector vs NIFTY 500 · 52 weeks
8/10Stocks leading NIFTY 500
5/10Stocks leading sector

Sector metric: 44.7 as of 2026-07-19 · BROADENING · falling.

The central tension: the companies with the most scale are not necessarily the companies creating the most change.

Start with scale. Then earnings trajectory. Then business quality. Only after those three agree should price leadership carry much weight.

Bottom line

Pharma - Others has outperformed NIFTY 500 by 16.3% over 52 weeks and 16.2% over 13 weeks. 8 of 10 covered companies beat NIFTY on Mansfield relative strength, while 5 of 10 beat the sector itself. Unichem Laboratories Ltd leads with revenue of ₹2,202 crore, based on 10 of 10 comparable companies through Mar 2026.

Companies
10
complete canonical membership
Combined market value
₹20.2K Cr
Sun Pharma Advanced Research Company Ltd
Revenue growing
10/10
positive TTM year-on-year growth
Beating NIFTY 500
8/10
positive Mansfield relative strength
Comparing 5 of 10
04 · research priority, made explicit

4-Factor Sector Score

An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment.

Growth & earnings · 35%Capital efficiency · 25%Valuation · 20%Relative strength · 20%
JOJO Ltd has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 69.3% evidence confidence.
TTK Healthcare Ltd looks inexpensive relative to peers or its own history, but its earnings trajectory has not yet earned the valuation signal.
Madhuveer Com 18 Network Ltd has stronger price confirmation than earnings confirmation; that is a research prompt, not permission to chase.
How this score is built, and what the marks mean

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1JOJO Ltd531910 66.2/100Favorable setup69% evidence TURNING 30.0/35 Revenue 100% · PAT 100% · OPM change 115.2 pp 95% evidence 13.6/25 ROCE 17% · OPM 48.1% 76% evidence 8.9/20 P/E 152× · PEG — 15% evidence 13.7/20 RS sector 4.3% · RS bench 9.9% · 1Y 21%1 of 10 weeks ahead 70% evidence
Exact sum: 30 + 13.6 + 8.9 + 13.7 = 66.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
2Shukra Pharmaceuticals LtdSHUKRAPHAR 65.3/100Favorable setup65% evidence 21.8/35 Revenue 100% · PAT 100% · OPM change 32 pp 83% evidence 17.2/25 ROCE 21.8% · OPM 69% 76% evidence 9.3/20 P/E 62.2× · PEG — 15% evidence 17.0/20 RS sector 49.8% · RS bench 40.2% · 1Y 112.2%9 of 12 weeks ahead to 2026-03-08 70% evidence
Exact sum: 21.8 + 17.2 + 9.3 + 17 = 65.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
3Sun Pharma Advanced Research Company LtdSPARC 64.1/100Mixed-positive evidence79% evidence LEADER 17.7/35 Revenue 100% · PAT 100% · OPM change 292 pp 71% evidence 19.2/25 ROCE 164% · OPM 96% 95% evidence 9.2/20 P/E 4.3× · PEG — 50% evidence 18.0/20 RS sector 15.9% · RS bench 30.5% · 1Y 36%12 of 12 weeks ahead 100% evidence
Exact sum: 17.7 + 19.2 + 9.2 + 18 = 64.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
4Remus Pharmaceuticals LtdREMUS 51.5/100Mixed-positive evidence70% evidence FADING 19.8/35 Revenue 100% · PAT 100% · OPM change 0 pp 48% evidence 13.9/25 ROCE 16.8% · OPM 7% 95% evidence 12.1/20 P/E 22.9× · PEG — 50% evidence 5.7/20 RS sector -14.9% · RS bench -2.5% · 1Y -26.4%9 of 12 weeks ahead 100% evidence
Exact sum: 19.8 + 13.9 + 12.1 + 5.7 = 51.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
5Jenburkt Pharmaceuticals Ltd524731 50.6/100Mixed-positive evidence82% evidence 16.9/35 Revenue 11.8% · PAT 6.1% · OPM change 6 pp 95% evidence 19.7/25 ROCE 27.2% · OPM 32% 76% evidence 10.1/20 P/E 13.2× · PEG — 50% evidence 3.9/20 RS sector -15.3% · RS bench 0.4% · 1Y -14.7%5 of 7 weeks ahead to 2026-06-28 100% evidence
Exact sum: 16.9 + 19.7 + 10.1 + 3.9 = 50.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
6Syncom Formulations (India) LtdSYNCOMF 49.3/100Mixed-negative evidence87% evidence ASLEEP 20.9/35 Revenue 4.9% · PAT 54% · OPM change 4 pp 95% evidence 17.3/25 ROCE 26.8% · OPM 16% 95% evidence 11.1/20 P/E 16.1× · PEG — 50% evidence 0.0/20 RS sector -23.1% · RS bench -11.6% · 1Y -27.6%7 of 12 weeks ahead 100% evidence
Exact sum: 20.9 + 17.3 + 11.1 + 0 = 49.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
7Madhuveer Com 18 Network LtdMADHUVEER 47.0/100Mixed-negative evidence65% evidence 15.6/35 Revenue 68.7% · PAT 12.8% · OPM change 18.4 pp 83% evidence 8.6/25 ROCE -1.1% · OPM 69.7% 76% evidence 8.5/20 P/E 660× · PEG — 15% evidence 14.3/20 RS sector 14.3% · RS bench 6.3% · 1Y 11.7%12 of 12 weeks ahead to 2026-03-08 70% evidence
Exact sum: 15.6 + 8.6 + 8.5 + 14.3 = 47 · Decision use: Price leads the evidence: RS versus the benchmark is 6.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
8Unichem Laboratories LtdUNICHEMLAB 42.2/100Mixed-negative evidence75% evidence BREAKING OUT 10.3/35 Revenue 4.4% · PAT 83.3% · OPM change -6 pp 95% evidence 6.3/25 ROCE 4.1% · OPM 8% 76% evidence 9.6/20 P/E 44.1× · PEG — 15% evidence 16.0/20 RS sector 2.7% · RS bench 17.4% · 1Y -19%9 of 12 weeks ahead 100% evidence
Exact sum: 10.3 + 6.3 + 9.6 + 16 = 42.2 · Decision use: Price leads the evidence: RS versus the benchmark is 17.4%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
9Panacea Biotec LtdPANACEABIO 39.0/100Mixed-negative evidence65% evidence TURNING 20.4/35 Revenue 14.4% · PAT 17.9% · OPM change 21.8 pp 74% evidence 0.3/25 ROCE -2.4% · OPM 1.5% 100% evidence 10.0/20 P/E — · PEG — 0% evidence 8.3/20 RS sector -10.2% · RS bench 2.1% · 1Y 0.8%10 of 10 weeks ahead 70% evidence
Exact sum: 20.4 + 0.3 + 10 + 8.3 = 39 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
10TTK Healthcare LtdTTKHLTCARE 38.2/100Mixed-negative evidence81% evidence TURNING 10.4/35 Revenue 7% · PAT -19.5% · OPM change -1 pp 95% evidence 8.3/25 ROCE 8% · OPM 5% 95% evidence 13.8/20 P/E 21.1× · PEG — 50% evidence 5.7/20 RS sector -20.5% · RS bench 0.4% · 1Y -20.7%4 of 10 weeks ahead 70% evidence
Exact sum: 10.4 + 8.3 + 13.8 + 5.7 = 38.2 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
05 · what price has already done

Market action

Shukra Pharmaceuticals Ltd has the strongest one-year price move in Pharma - Others at +112.2%. It also leads on Mansfield relative strength against NIFTY at +40.2%. 8 of 10 covered companies are above zero on that measure. Every line covers 313 weekly closes through 2026-07-31.

Price and relative strength

Every company, the sector's own index and NIFTY 500 all start level on the left edge of the window, so only the distance between the lines counts — the highest line has risen the most since then, and the chart at the top of this page is drawn the same way. It opens on one year; the buttons beside it stretch that to three or five.

06 · compare level, then change

Revenue Scale & Growth Durability

Unichem Laboratories Ltd has the highest Revenue among the 10 Pharma - Others companies compared here, at ₹2,202 crore. Sun Pharma Advanced Research Company Ltd is next at ₹1,879 crore. JOJO Ltd has the highest Revenue growth at the 100% top of the scoring scale, so level and change sit with different companies.

What the numbers say: Unichem Laboratories Ltd is the scale leader at ₹2,202 crore, 17.2% ahead of Sun Pharma Advanced Research Company Ltd. JOJO Ltd's growth is stored at the ≥100% scoring cap; the uncapped TTM change is 446.9% from a ₹24 crore base, with 15 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale.

LeaderUnichem Laboratories Ltd · ₹2,202 crore
Gap17.2% versus #2 · Sun Pharma Advanced Research Company Ltd
Persistence6/8 recent comparable periods
Coverage10/10 companies · 145 observations

Investor read: Unichem Laboratories Ltd is the scale benchmark; JOJO Ltd is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns.

This conclusion weakens if: Unichem Laboratories Ltd's growth falls below JOJO Ltd's for two consecutive comparable reports while operating margin also compresses.

Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.
Revenuelargest
1Unichem Laboratories Ltd UNICHEMLAB₹2.2K Cr
2Sun Pharma Advanced Research Company Ltd SPARC₹1.9K Cr
3Remus Pharmaceuticals Ltd REMUS⚠ unverified₹1.5K Cr
4TTK Healthcare Ltd TTKHLTCARE⚠ unverified₹857 Cr
5Panacea Biotec Ltd PANACEABIO₹640 Cr
Revenue growthfastest growers
1JOJO Ltd 531910100%
2Remus Pharmaceuticals Ltd REMUS⚠ unverified100%
3Shukra Pharmaceuticals Ltd SHUKRAPHAR100%
4Sun Pharma Advanced Research Company Ltd SPARC100%
5Madhuveer Com 18 Network Ltd MADHUVEER69%
Revenue · company comparison
10/10 level · 10/10 change

On every company-comparison chart on this page: solid lines show level, dotted lines show change when “Both” is selected, and a missing report breaks the line rather than being invented.

All-company data · latest reported quarter

In every all-company table on this page, each figure is the company’s latest single reported quarter. The rankings above them use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.

CompanyRevenueRevenue growthReported
Sun Pharma Advanced Research Company Ltd SPARC₹1.9K Cr6,763%Mar 2026
Unichem Laboratories Ltd UNICHEMLAB₹575 Cr-2.0%Mar 2026
Remus Pharmaceuticals Ltd REMUS⚠ unverified₹453 Cr30%Mar 2026
TTK Healthcare Ltd TTKHLTCARE⚠ unverified₹218 Cr15%Mar 2026
Panacea Biotec Ltd PANACEABIO₹167 Cr26%Mar 2026
Syncom Formulations (India) Ltd SYNCOMF⚠ unverified₹135 Cr-9.4%Mar 2026
Jenburkt Pharmaceuticals Ltd 524731₹45 Cr9.8%Mar 2026
Shukra Pharmaceuticals Ltd SHUKRAPHAR₹39 Cr255%Dec 2025
JOJO Ltd 531910₹13 Cr781%Mar 2026
Madhuveer Com 18 Network Ltd MADHUVEER₹8 Cr257%Dec 2025
Full 20-quarter history · every available company

Revenue · reported quarter history

Jenburkt Pharmaceuticals Ltd · 524731

—
—
—
—
—
—
—
₹35 Cr
₹29 Cr
₹38 Cr
₹36 Cr
₹39 Cr
₹33 Cr
₹41 Cr
₹37 Cr
₹41 Cr
₹36 Cr
₹46 Cr
₹43 Cr
₹45 Cr

JOJO Ltd · 531910

—
—
—
—
—
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹5 Cr
₹0 Cr
₹1 Cr
₹2 Cr
₹1 Cr
₹2 Cr
₹1 Cr
₹8 Cr
₹13 Cr

Madhuveer Com 18 Network Ltd · MADHUVEER

—
—
—
—
—
—
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹5 Cr
₹0 Cr
₹1 Cr
₹2 Cr
₹1 Cr
₹2 Cr
₹1 Cr
₹8 Cr
—

Panacea Biotec Ltd · PANACEABIO

₹132 Cr
₹232 Cr
₹156 Cr
₹141 Cr
₹111 Cr
₹105 Cr
₹115 Cr
₹129 Cr
₹129 Cr
₹143 Cr
₹151 Cr
₹136 Cr
₹116 Cr
₹147 Cr
₹163 Cr
₹133 Cr
₹167 Cr
₹141 Cr
₹165 Cr
₹167 Cr

Remus Pharmaceuticals Ltd · REMUS⚠ unverified

—
—
—
₹14 Cr
—
₹20 Cr
—
₹25 Cr
—
₹29 Cr
—
₹185 Cr
—
₹273 Cr
—
₹348 Cr
—
₹400 Cr
—
₹453 Cr

Shukra Pharmaceuticals Ltd · SHUKRAPHAR

—
—
—
—
—
—
₹2 Cr
₹46 Cr
₹20 Cr
₹25 Cr
₹19 Cr
₹11 Cr
₹3 Cr
₹6 Cr
₹11 Cr
₹13 Cr
₹5 Cr
₹6 Cr
₹39 Cr
—

Sun Pharma Advanced Research Company Ltd · SPARC

₹22 Cr
₹28 Cr
₹62 Cr
₹25 Cr
₹28 Cr
₹32 Cr
₹131 Cr
₹48 Cr
₹24 Cr
₹21 Cr
₹14 Cr
₹17 Cr
₹17 Cr
₹13 Cr
₹15 Cr
₹27 Cr
₹10 Cr
₹8 Cr
₹8 Cr
₹1.9K Cr

Syncom Formulations (India) Ltd · SYNCOMF⚠ unverified

—
—
—
—
—
—
₹57 Cr
₹61 Cr
₹60 Cr
₹64 Cr
₹65 Cr
₹75 Cr
₹87 Cr
₹102 Cr
₹128 Cr
₹149 Cr
₹117 Cr
₹122 Cr
₹115 Cr
₹135 Cr

TTK Healthcare Ltd · TTKHLTCARE⚠ unverified

—
—
—
—
—
—
₹183 Cr
₹180 Cr
₹202 Cr
₹186 Cr
₹184 Cr
₹181 Cr
₹208 Cr
₹198 Cr
₹205 Cr
₹190 Cr
₹226 Cr
₹204 Cr
₹209 Cr
₹218 Cr

Unichem Laboratories Ltd · UNICHEMLAB

—
—
—
—
—
—
₹302 Cr
₹402 Cr
₹423 Cr
₹416 Cr
₹466 Cr
₹432 Cr
₹483 Cr
₹507 Cr
₹533 Cr
₹587 Cr
₹527 Cr
₹579 Cr
₹521 Cr
₹575 Cr

Revenue growth · reported quarter history

Jenburkt Pharmaceuticals Ltd · 524731

—
—
—
—
—
—
—
—
—
—
—
11%
14%
7.9%
2.8%
5.1%
9.1%
12%
16%
9.8%

JOJO Ltd · 531910

—
—
—
—
—
—
—
—
—
800%
150%
—
-33%
611%
4,460%
-69%
4,375%
130%
257%
781%

Madhuveer Com 18 Network Ltd · MADHUVEER

—
—
—
—
—
—
—
—
—
—
150%
—
-33%
611%
4,460%
-69%
4,375%
130%
257%
—

Panacea Biotec Ltd · PANACEABIO

—
—
—
—
-16%
-55%
-26%
-8.6%
16%
36%
31%
5.8%
-10%
3.0%
8.6%
-2.9%
44%
-4.2%
1.0%
26%

Remus Pharmaceuticals Ltd · REMUS⚠ unverified

—
—
—
—
—
—
—
79%
—
45%
—
640%
—
841%
—
88%
—
47%
—
30%

Shukra Pharmaceuticals Ltd · SHUKRAPHAR

—
—
—
—
—
—
—
—
—
—
850%
-76%
-85%
-76%
-42%
18%
67%
0.0%
255%
—

Sun Pharma Advanced Research Company Ltd · SPARC

—
—
—
—
27%
14%
111%
92%
-14%
-34%
-89%
-65%
-29%
-38%
7.1%
59%
-41%
-38%
-47%
6,763%

Syncom Formulations (India) Ltd · SYNCOMF⚠ unverified

—
—
—
—
—
—
—
—
—
—
14%
23%
45%
59%
97%
99%
34%
20%
-10%
-9.4%

TTK Healthcare Ltd · TTKHLTCARE⚠ unverified

—
—
—
—
—
—
—
—
—
—
0.6%
0.6%
3.0%
6.5%
11%
5.0%
8.7%
3.0%
2.0%
15%

Unichem Laboratories Ltd · UNICHEMLAB

—
—
—
—
—
—
—
—
—
—
54%
7.5%
14%
22%
14%
36%
9.1%
14%
-2.3%
-2.0%
07 · compare level, then change

Operating Economics & Margin Trend

Sun Pharma Advanced Research Company Ltd has the highest OPM among the 10 Pharma - Others companies compared here, at 96%. Madhuveer Com 18 Network Ltd is next at 69.7%. The same company also holds the highest Margin change, at +292 percentage points. 10 of 10 companies report a comparable reading, the latest through Mar 2026.

What the numbers say: Sun Pharma Advanced Research Company Ltd leads both opm at 96% and margin change at +292 percentage points.

LeaderSun Pharma Advanced Research Company Ltd · 96%
Gap37.7% versus #2 · Madhuveer Com 18 Network Ltd
Persistence4/8 recent comparable periods
Coverage10/10 companies · 180 observations

Investor read: Sun Pharma Advanced Research Company Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current margin change signal.

Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.
OPMhighest
1Sun Pharma Advanced Research Company Ltd SPARC96%
2Madhuveer Com 18 Network Ltd MADHUVEER70%
3Shukra Pharmaceuticals Ltd SHUKRAPHAR69%
4JOJO Ltd 53191048%
5Jenburkt Pharmaceuticals Ltd 52473132%
Margin changefastest expanders
1Sun Pharma Advanced Research Company Ltd SPARC+292.0 pp
2JOJO Ltd 531910+115.2 pp
3Shukra Pharmaceuticals Ltd SHUKRAPHAR+32.0 pp
4Panacea Biotec Ltd PANACEABIO+21.8 pp
5Madhuveer Com 18 Network Ltd MADHUVEER+18.4 pp
Operating margin · company comparison
10/10 level · 10/10 change
All-company data · latest reported quarter
CompanyOPMMargin changeReported
Sun Pharma Advanced Research Company Ltd SPARC96%+292.0 ppMar 2026
Madhuveer Com 18 Network Ltd MADHUVEER70%+18.4 ppDec 2025
Shukra Pharmaceuticals Ltd SHUKRAPHAR69%+32.0 ppDec 2025
JOJO Ltd 53191048%+115.2 ppMar 2026
Jenburkt Pharmaceuticals Ltd 52473132%+6.0 ppMar 2026
Syncom Formulations (India) Ltd SYNCOMF⚠ unverified16%+4.0 ppMar 2026
Unichem Laboratories Ltd UNICHEMLAB8.0%−6.0 ppMar 2026
Remus Pharmaceuticals Ltd REMUS⚠ unverified7.0%0.0 ppMar 2026
TTK Healthcare Ltd TTKHLTCARE⚠ unverified5.0%−1.0 ppMar 2026
Panacea Biotec Ltd PANACEABIO1.5%+21.8 ppMar 2026
Full 20-quarter history · every available company

OPM · reported quarter history

Jenburkt Pharmaceuticals Ltd · 524731

20%
29%
21%
16%
23%
24%
20%
21%
24%
24%
20%
25%
29%
28%
24%
26%
25%
29%
17%
32%

JOJO Ltd · 531910

—
—
91%
-25%
17%
100%
50%
0.0%
17%
-222%
20%
44%
—
-52%
51%
-67%
-8.4%
-89%
70%
48%

Madhuveer Com 18 Network Ltd · MADHUVEER

—
—
91%
-25%
17%
100%
50%
—
17%
-222%
20%
44%
—
-52%
51%
-67%
-8.4%
-89%
70%
—

Panacea Biotec Ltd · PANACEABIO

-1.2%
2.6%
7.6%
-21%
-72%
-3.7%
-7.5%
-4.4%
-8.0%
-2.5%
-0.1%
-4.4%
-12%
4.8%
4.9%
-20%
-0.7%
-13%
7.1%
1.5%

Remus Pharmaceuticals Ltd · REMUS⚠ unverified

—
—
—
11%
—
23%
—
23%
—
32%
—
11%
—
8.0%
—
7.0%
—
7.0%
—
7.0%

Shukra Pharmaceuticals Ltd · SHUKRAPHAR

7.1%
-65%
13%
18%
15%
13%
12%
8.0%
2.0%
21%
51%
41%
25%
12%
37%
55%
24%
-7.0%
69%
—

Sun Pharma Advanced Research Company Ltd · SPARC

-245%
-196%
-18%
-264%
-275%
-198%
12%
-188%
-427%
-432%
-740%
-639%
-555%
-800%
-494%
-196%
-540%
-836%
-670%
96%

Syncom Formulations (India) Ltd · SYNCOMF⚠ unverified

14%
11%
8.5%
3.5%
6.8%
7.9%
10%
10%
11%
10%
11%
13%
12%
12%
12%
12%
14%
15%
18%
16%

TTK Healthcare Ltd · TTKHLTCARE⚠ unverified

4.6%
1.8%
5.3%
3.0%
2.0%
2.4%
5.0%
8.0%
5.0%
5.0%
2.9%
7.0%
3.3%
4.2%
3.8%
6.0%
1.2%
2.6%
3.4%
5.0%

Unichem Laboratories Ltd · UNICHEMLAB

-0.6%
2.2%
-0.5%
19%
-0.3%
-5.6%
-14%
4.1%
7.0%
2.1%
7.0%
6.0%
8.0%
11%
16%
14%
4.3%
11%
9.0%
8.0%

Margin change · reported quarter history

Jenburkt Pharmaceuticals Ltd · 524731

+16.2 pp
+5.4 pp
−0.9 pp
−0.6 pp
+3.7 pp
−4.9 pp
−0.9 pp
+4.6 pp
+0.6 pp
−0.0 pp
−0.2 pp
+4.0 pp
+5.0 pp
+4.0 pp
+4.0 pp
+1.0 pp
−4.0 pp
+1.0 pp
−7.0 pp
+6.0 pp

JOJO Ltd · 531910

—
—
+107.6 pp
−25.0 pp
—
—
−40.9 pp
+25.0 pp
0.0 pp
−322.2 pp
−30.0 pp
+44.1 pp
−1,716.7 pp
+170.7 pp
+31.3 pp
−111.2 pp
+1,691.6 pp
−37.6 pp
+18.4 pp
+115.2 pp

Madhuveer Com 18 Network Ltd · MADHUVEER

—
—
+107.6 pp
−25.0 pp
—
—
−40.9 pp
—
0.0 pp
−322.2 pp
−30.0 pp
—
−1,716.7 pp
+170.7 pp
+31.3 pp
−111.2 pp
+1,691.6 pp
−37.6 pp
+18.4 pp
—

Panacea Biotec Ltd · PANACEABIO

−17.4 pp
−18.1 pp
−3.0 pp
−22.0 pp
−70.9 pp
−6.2 pp
−15.1 pp
+17.1 pp
+64.1 pp
+1.2 pp
+7.4 pp
−0.0 pp
−4.1 pp
+7.2 pp
+5.0 pp
−15.9 pp
+11.4 pp
−17.4 pp
+2.2 pp
+21.8 pp

Remus Pharmaceuticals Ltd · REMUS⚠ unverified

—
—
—
—
—
—
—
+12.0 pp
—
+9.0 pp
—
−12.0 pp
—
−24.0 pp
—
−4.0 pp
—
−1.0 pp
—
0.0 pp

Shukra Pharmaceuticals Ltd · SHUKRAPHAR

−14.5 pp
−85.9 pp
+3.4 pp
+6.9 pp
+7.5 pp
+77.7 pp
−0.8 pp
−9.7 pp
−12.6 pp
+8.4 pp
+39.0 pp
+33.0 pp
+23.0 pp
−9.0 pp
−14.0 pp
+14.0 pp
−1.0 pp
−19.0 pp
+32.0 pp
—

Sun Pharma Advanced Research Company Ltd · SPARC

−277.3 pp
+270.8 pp
+270.5 pp
−83.9 pp
−30.3 pp
−2.3 pp
+30.5 pp
+75.6 pp
−152.2 pp
−233.5 pp
−752.3 pp
−451.0 pp
−128.0 pp
−368.0 pp
+246.0 pp
+443.0 pp
+15.0 pp
−36.0 pp
−176.0 pp
+292.0 pp

Syncom Formulations (India) Ltd · SYNCOMF⚠ unverified

−0.4 pp
−7.9 pp
−6.9 pp
−9.4 pp
−6.9 pp
−2.8 pp
+1.5 pp
+6.5 pp
+4.2 pp
+2.1 pp
+1.0 pp
+3.0 pp
+1.0 pp
+2.0 pp
+1.0 pp
−1.0 pp
+2.0 pp
+3.0 pp
+6.0 pp
+4.0 pp

TTK Healthcare Ltd · TTKHLTCARE⚠ unverified

+5.2 pp
−3.9 pp
−1.3 pp
−3.9 pp
−2.7 pp
+0.6 pp
−0.3 pp
+5.0 pp
+3.0 pp
+2.6 pp
−2.1 pp
−1.0 pp
−1.7 pp
−0.8 pp
+0.9 pp
−1.0 pp
−2.1 pp
−1.6 pp
−0.4 pp
−1.0 pp

Unichem Laboratories Ltd · UNICHEMLAB

−4.4 pp
−7.2 pp
−9.6 pp
+11.6 pp
+0.3 pp
−7.8 pp
−13.6 pp
−14.4 pp
+7.3 pp
+7.7 pp
+21.0 pp
+1.9 pp
+1.0 pp
+8.9 pp
+9.0 pp
+8.0 pp
−3.7 pp
0.0 pp
−7.0 pp
−6.0 pp
08 · compare level, then change

Profit Scale & Acceleration

Sun Pharma Advanced Research Company Ltd has the highest Net profit among the 10 Pharma - Others companies compared here, at ₹1,553 crore. Unichem Laboratories Ltd is next at ₹253 crore. JOJO Ltd has the highest Profit growth at the 100% top of the scoring scale, so level and change sit with different companies.

What the numbers say: Sun Pharma Advanced Research Company Ltd leads with ₹1,553 crore of TTM profit, 513.8% above Unichem Laboratories Ltd. JOJO Ltd shows ≥100% on the scoring scale growth from a ₹6 crore profit base. Compare the size of the base and persistence before ranking acceleration above profit scale.

LeaderSun Pharma Advanced Research Company Ltd · ₹1,553 crore
Gap513.8% versus #2 · Unichem Laboratories Ltd
Persistence0/1 recent comparable periods
Coverage10/10 companies · 145 observations

Investor read: Sun Pharma Advanced Research Company Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.

Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.
Net profitlargest
1Sun Pharma Advanced Research Company Ltd SPARC₹1.6K Cr
2Unichem Laboratories Ltd UNICHEMLAB₹253 Cr
3Remus Pharmaceuticals Ltd REMUS⚠ unverified₹87 Cr
4Syncom Formulations (India) Ltd SYNCOMF⚠ unverified₹77 Cr
5TTK Healthcare Ltd TTKHLTCARE⚠ unverified₹66 Cr
Profit growthfastest growers
1JOJO Ltd 531910100%
2Remus Pharmaceuticals Ltd REMUS⚠ unverified100%
3Shukra Pharmaceuticals Ltd SHUKRAPHAR100%
4Unichem Laboratories Ltd UNICHEMLAB83%
5Syncom Formulations (India) Ltd SYNCOMF⚠ unverified54%
Net profit · company comparison
10/10 level · 8/10 change
All-company data · latest reported quarter
CompanyNet profitProfit growthReported
Sun Pharma Advanced Research Company Ltd SPARC₹1.8K Cr-1,100%Mar 2026
Syncom Formulations (India) Ltd SYNCOMF⚠ unverified₹25 Cr39%Mar 2026
Remus Pharmaceuticals Ltd REMUS⚠ unverified₹25 Cr19%Mar 2026
TTK Healthcare Ltd TTKHLTCARE⚠ unverified₹22 Cr38%Mar 2026
Shukra Pharmaceuticals Ltd SHUKRAPHAR₹20 Cr567%Dec 2025
Jenburkt Pharmaceuticals Ltd 524731₹11 Cr22%Mar 2026
Unichem Laboratories Ltd UNICHEMLAB₹11 Cr-79%Mar 2026
JOJO Ltd 531910₹5 Cr7,883%Mar 2026
Madhuveer Com 18 Network Ltd MADHUVEER₹1 Cr3.0%Dec 2025
Panacea Biotec Ltd PANACEABIO₹-1 Cr-12%Mar 2026
Full 20-quarter history · every available company

Net profit · reported quarter history

Jenburkt Pharmaceuticals Ltd · 524731

—
—
—
—
—
—
—
₹6 Cr
₹5 Cr
₹7 Cr
₹5 Cr
₹8 Cr
₹7 Cr
₹10 Cr
₹7 Cr
₹9 Cr
₹8 Cr
₹10 Cr
₹6 Cr
₹11 Cr

JOJO Ltd · 531910

—
—
—
—
—
₹0 Cr
₹0 Cr
₹-0 Cr
₹0 Cr
₹-0 Cr
₹0 Cr
₹3 Cr
₹-2 Cr
₹-1 Cr
₹1 Cr
₹0 Cr
₹-1 Cr
₹0 Cr
₹1 Cr
₹5 Cr

Madhuveer Com 18 Network Ltd · MADHUVEER

—
—
—
—
—
—
₹0 Cr
₹-0 Cr
₹0 Cr
₹-0 Cr
₹0 Cr
₹3 Cr
₹-2 Cr
₹-1 Cr
₹1 Cr
₹0 Cr
₹-1 Cr
₹0 Cr
₹1 Cr
—

Panacea Biotec Ltd · PANACEABIO

₹-57 Cr
₹-53 Cr
₹-49 Cr
₹1.2K Cr
₹-56 Cr
₹16 Cr
₹19 Cr
₹-13 Cr
₹11 Cr
₹-8 Cr
₹-2 Cr
₹-2 Cr
₹-16 Cr
₹5 Cr
₹4 Cr
₹-2 Cr
₹4 Cr
₹-14 Cr
₹4 Cr
₹-1 Cr

Remus Pharmaceuticals Ltd · REMUS⚠ unverified

—
—
—
₹1 Cr
—
₹4 Cr
—
₹4 Cr
—
₹6 Cr
—
₹19 Cr
—
₹19 Cr
—
₹21 Cr
—
₹22 Cr
—
₹25 Cr

Shukra Pharmaceuticals Ltd · SHUKRAPHAR

—
—
—
—
—
—
₹0 Cr
₹4 Cr
₹0 Cr
₹5 Cr
₹9 Cr
₹4 Cr
₹0 Cr
₹1 Cr
₹3 Cr
₹5 Cr
₹1 Cr
₹2 Cr
₹20 Cr
—

Sun Pharma Advanced Research Company Ltd · SPARC

₹-61 Cr
₹-55 Cr
₹-16 Cr
₹-71 Cr
₹-82 Cr
₹-68 Cr
₹10 Cr
₹-82 Cr
₹-95 Cr
₹-86 Cr
₹-100 Cr
₹-106 Cr
₹-96 Cr
₹-107 Cr
₹-80 Cr
₹-60 Cr
₹-52 Cr
₹-76 Cr
₹-80 Cr
₹1.8K Cr

Syncom Formulations (India) Ltd · SYNCOMF⚠ unverified

—
—
—
—
—
—
₹4 Cr
₹8 Cr
₹4 Cr
₹7 Cr
₹7 Cr
₹7 Cr
₹8 Cr
₹11 Cr
₹13 Cr
₹18 Cr
₹16 Cr
₹17 Cr
₹19 Cr
₹25 Cr

TTK Healthcare Ltd · TTKHLTCARE⚠ unverified

—
—
—
—
—
—
₹12 Cr
₹17 Cr
₹16 Cr
₹16 Cr
₹13 Cr
₹18 Cr
₹32 Cr
₹17 Cr
₹17 Cr
₹16 Cr
₹13 Cr
₹20 Cr
₹11 Cr
₹22 Cr

Unichem Laboratories Ltd · UNICHEMLAB

—
—
—
—
—
—
₹-64 Cr
₹-44 Cr
₹-1 Cr
₹-24 Cr
₹73 Cr
₹-129 Cr
₹2 Cr
₹25 Cr
₹58 Cr
₹53 Cr
₹-10 Cr
₹-12 Cr
₹264 Cr
₹11 Cr

Profit growth · reported quarter history

Jenburkt Pharmaceuticals Ltd · 524731

—
—
—
—
—
—
—
—
—
—
—
33%
40%
43%
40%
13%
14%
0.0%
-14%
22%

JOJO Ltd · 531910

—
—
—
—
—
—
—
—
—
—
100%
—
—
—
4,850%
-98%
—
—
3.0%
7,883%

Madhuveer Com 18 Network Ltd · MADHUVEER

—
—
—
—
—
—
—
—
—
—
100%
—
—
—
4,850%
-98%
—
—
3.0%
—

Panacea Biotec Ltd · PANACEABIO

—
—
—
—
—
—
—
-101%
—
-152%
-111%
—
-245%
—
—
—
—
-397%
-12%
—

Remus Pharmaceuticals Ltd · REMUS⚠ unverified

—
—
—
—
—
—
—
300%
—
50%
—
375%
—
217%
—
11%
—
16%
—
19%

Shukra Pharmaceuticals Ltd · SHUKRAPHAR

—
—
—
—
—
—
—
—
—
—
—
0.0%
—
-80%
-67%
25%
—
100%
567%
—

Sun Pharma Advanced Research Company Ltd · SPARC

—
—
—
—
—
—
—
—
—
—
-1,100%
—
—
—
—
—
—
—
—
—

Syncom Formulations (India) Ltd · SYNCOMF⚠ unverified

—
—
—
—
—
—
—
—
—
—
75%
-13%
100%
57%
86%
157%
100%
55%
46%
39%

TTK Healthcare Ltd · TTKHLTCARE⚠ unverified

—
—
—
—
—
—
—
—
—
—
8.3%
5.9%
100%
6.3%
31%
-11%
-59%
18%
-35%
38%

Unichem Laboratories Ltd · UNICHEMLAB

—
—
—
—
—
—
—
—
—
—
—
—
—
—
-21%
—
-600%
-148%
355%
-79%
09 · compare level, then change

Return On Capital Employed

Sun Pharma Advanced Research Company Ltd has the highest ROCE among the 10 Pharma - Others companies compared here, at 164%. Jenburkt Pharmaceuticals Ltd is next at 27.2%. JOJO Ltd has the highest ROCE change at +18.1 percentage points, so level and change sit with different companies. 10 of 10 companies report a comparable reading, the latest through Mar 2026.

What the numbers say: Sun Pharma Advanced Research Company Ltd leads ROCE at 164%, 136.8 percentage points above Jenburkt Pharmaceuticals Ltd. JOJO Ltd has the strongest latest improvement at +18.1 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability.

LeaderSun Pharma Advanced Research Company Ltd · 164%
Gap502.9% versus #2 · Jenburkt Pharmaceuticals Ltd
Persistence2/8 recent comparable periods
Coverage10/10 companies · 64 observations

Investor read: Sun Pharma Advanced Research Company Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current roce change signal.

ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.
ROCEhighest
1Sun Pharma Advanced Research Company Ltd SPARC164%
2Jenburkt Pharmaceuticals Ltd 52473127%
3Syncom Formulations (India) Ltd SYNCOMF⚠ unverified27%
4Shukra Pharmaceuticals Ltd SHUKRAPHAR22%
5JOJO Ltd 53191017%
ROCE changefastest improvers
1JOJO Ltd 531910+18.1 pp
2Syncom Formulations (India) Ltd SYNCOMF⚠ unverified+2.5 pp
3Panacea Biotec Ltd PANACEABIO+1.2 pp
4Jenburkt Pharmaceuticals Ltd 5247310.0 pp
5TTK Healthcare Ltd TTKHLTCARE⚠ unverified−0.3 pp
Return on capital · company comparison
10/10 level · 10/10 change

Withheld from this chart: Unichem Laboratories Ltd (UNICHEMLAB) — its two data sources disagree by up to 338% on reported income across 14 comparable periods, so its derived ratios are withheld. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.

All-company data · latest reported quarter
CompanyROCEROCE changeReported
Sun Pharma Advanced Research Company Ltd SPARC112%−750.2 ppMar 2026
Syncom Formulations (India) Ltd SYNCOMF⚠ unverified17%+2.5 ppMar 2026
Remus Pharmaceuticals Ltd REMUS⚠ unverified13%−1.5 ppMar 2026
TTK Healthcare Ltd TTKHLTCARE⚠ unverified1.6%−0.3 ppMar 2026
Panacea Biotec Ltd PANACEABIO-4.1%+1.2 ppMar 2026
Full 20-quarter history · every available company

ROCE · reported quarter history

Panacea Biotec Ltd · PANACEABIO

—
-1.5%
—
-4.9%
—
-12%
—
-11%
—
-4.8%
2.7%
-4.5%
-2.7%
-4.2%
-0.7%
-5.3%
2.1%
-7.1%
0.0%
-4.1%

Remus Pharmaceuticals Ltd · REMUS⚠ unverified

—
—
—
—
—
—
—
—
—
—
—
15%
—
31%
—
14%
—
13%
—
13%

Sun Pharma Advanced Research Company Ltd · SPARC

—
-251%
—
-181%
—
625%
—
-34%
—
-61%
-129%
-165%
-86%
-991%
-154%
862%
-195%
150%
-574%
112%

Syncom Formulations (India) Ltd · SYNCOMF⚠ unverified

—
14%
—
7.0%
—
4.3%
—
5.7%
—
7.2%
14%
8.3%
14%
11%
18%
14%
23%
16%
25%
17%

TTK Healthcare Ltd · TTKHLTCARE⚠ unverified

—
8.2%
—
—
—
1.6%
—
1.9%
—
3.1%
9.1%
2.4%
11%
2.1%
11%
1.9%
8.7%
1.2%
7.4%
1.6%

ROCE change · reported quarter history

Panacea Biotec Ltd · PANACEABIO

—
—
—
—
—
−10.9 pp
—
−6.0 pp
—
+7.6 pp
—
+6.4 pp
—
+0.6 pp
−3.4 pp
−0.8 pp
+4.8 pp
−2.9 pp
+0.7 pp
+1.2 pp

Remus Pharmaceuticals Ltd · REMUS⚠ unverified

—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
−0.4 pp
—
−17.6 pp
—
−1.5 pp

Sun Pharma Advanced Research Company Ltd · SPARC

—
—
—
—
—
+875.8 pp
—
+146.5 pp
—
−686.1 pp
—
−130.3 pp
—
−929.7 pp
−24.6 pp
+1,027.0 pp
−109.0 pp
+1,140.7 pp
−420.2 pp
−750.2 pp

Syncom Formulations (India) Ltd · SYNCOMF⚠ unverified

—
—
—
—
—
−9.8 pp
—
−1.3 pp
—
+2.9 pp
—
+2.6 pp
—
+3.3 pp
+3.7 pp
+5.7 pp
+8.8 pp
+5.1 pp
+7.6 pp
+2.5 pp

TTK Healthcare Ltd · TTKHLTCARE⚠ unverified

—
—
—
—
—
−6.6 pp
—
—
—
+1.5 pp
—
+0.5 pp
—
−1.0 pp
+2.3 pp
−0.5 pp
−2.3 pp
−0.9 pp
−4.0 pp
−0.3 pp
10 · compare level, then change

Valuation Against Growth & Quality

No company in this Pharma - Others comparison reports a valuation figure this section can compare, so the PEG rank is empty. On P/E, Sun Pharma Advanced Research Company Ltd is lowest at 4.28×, across 9 of 10 companies with a usable reading.

What the numbers say: There is not enough comparable evidence to name a reliable peg leader.

LeaderNo comparable leader
GapNot enough peers
PersistenceNot enough history
Coverage0/10 companies · 0 observations

Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.

This conclusion weakens if: The next two comparable reports reverse the current p/e signal.

PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.
PEGlowest PEG
—Not enough comparable data—
P/Elowest P/E
1Sun Pharma Advanced Research Company Ltd SPARC4.3
2Jenburkt Pharmaceuticals Ltd 52473113.2
3Syncom Formulations (India) Ltd SYNCOMF⚠ unverified16.1
4TTK Healthcare Ltd TTKHLTCARE⚠ unverified21.1
5Remus Pharmaceuticals Ltd REMUS⚠ unverified22.9
Valuation · company comparison
0/10 level · 9/10 change
All-company data · latest reported quarter
CompanyPEGP/EReported
Jenburkt Pharmaceuticals Ltd 524731—13.8Mar 2026
JOJO Ltd 531910—572.8Mar 2026
Sun Pharma Advanced Research Company Ltd SPARC—2.4Mar 2026
Unichem Laboratories Ltd UNICHEMLAB—19.0Mar 2026
Panacea Biotec Ltd PANACEABIO—-337.7Mar 2026
Shukra Pharmaceuticals Ltd SHUKRAPHAR—217.6Dec 2025
TTK Healthcare Ltd TTKHLTCARE⚠ unverified—15.6Mar 2026
Syncom Formulations (India) Ltd SYNCOMF⚠ unverified—15.0Mar 2026
Remus Pharmaceuticals Ltd REMUS⚠ unverified—21.6Mar 2026
Madhuveer Com 18 Network Ltd MADHUVEER—669.7Dec 2025
Full 20-quarter history · every available company

No consistent historical series is available for peg.

P/E · reported quarter history

Jenburkt Pharmaceuticals Ltd · 524731

13.6
11.1
10.9
10.8
10.0
10.6
13.3
14.1
13.3
13.1
12.4
12.4
14.8
17.1
17.3
14.2
18.3
14.7
14.4
13.8

JOJO Ltd · 531910

—
—
—
—
—
—
—
—
3,400.0
3,069.0
—
—
—
87.9
190.6
118.3
110.4
—
669.7
572.8

Madhuveer Com 18 Network Ltd · MADHUVEER

—
—
—
—
—
—
—
—
3,400.0
3,069.0
—
—
—
87.9
190.6
118.3
110.4
—
669.7
—

Panacea Biotec Ltd · PANACEABIO

—
—
—
0.8
—
0.7
0.7
—
23.1
—
—
—
—
-123.9
-314.9
—
227.6
—
-296.3
-337.7

Remus Pharmaceuticals Ltd · REMUS⚠ unverified

—
—
—
—
—
—
—
—
—
132.8
—
49.5
—
76.0
—
47.1
—
31.0
—
21.6

Shukra Pharmaceuticals Ltd · SHUKRAPHAR

—
38.0
44.0
36.0
26.0
52.0
23.0
58.5
46.6
38.9
14.8
19.0
25.9
15.7
37.5
115.0
62.1
149.9
217.6
—

Sun Pharma Advanced Research Company Ltd · SPARC

—
—
—
—
—
—
-27.1
—
—
—
—
—
—
—
—
—
—
—
—
2.4

Syncom Formulations (India) Ltd · SYNCOMF⚠ unverified

56.7
49.8
94.0
82.4
57.1
58.4
63.4
32.8
36.1
38.1
60.2
39.9
46.1
73.3
56.7
39.2
36.3
27.4
21.5
15.0

TTK Healthcare Ltd · TTKHLTCARE⚠ unverified

23.1
20.9
41.0
49.1
62.8
79.8
62.9
51.5
2.8
29.3
31.2
32.1
33.1
37.2
31.0
24.5
25.6
24.2
20.8
15.6

Unichem Laboratories Ltd · UNICHEMLAB

66.0
87.8
82.7
—
51.2
129.1
149.3
—
—
—
—
—
—
—
191.4
63.4
30.3
27.0
21.5
19.0
11 · before the conclusion, check the blind spots

What can make this comparison misleading?

This Pharma - Others comparison names 7 specific ways its own evidence can mislead, all listed below. All 10 companies here report on comparable dates, so no rank carries a stale marker. 3 draw at least one figure from a second feed with too little overlap to cross-check. 1 has second-feed figures withheld because the two sources disagree.

Keep these limits visible

  • A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason.
  • A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment.
  • The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed.
  • An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
  • 3 companies draw at least one figure from a second data feed with too little overlapping history to cross-check against the primary source; they are marked unverified wherever those figures appear.
  • 1 company is missing from the second-feed metrics by decision, not by absence: the two sources disagree, so nothing from the second is drawn. Read those rows as narrower evidence, never as a weaker business.
  • Thin comparisons: Valuation have fewer than three usable current readings.
12 · evidence and freshness

How was this comparison built?

This comparison is built from the reported filings of 10 Pharma - Others companies, normalized to a common ₹ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Mar 2026 and market data through 2026-07-31. A second data feed fills gaps only after identity and scale reconciliation, and missing observations are never interpolated.

FundamentalsThrough Mar 2026 · up to 20 quarters per company
Market dataThrough 2026-07-31 · weekly price and relative-strength history
Derived metricsGrowth, changes and PEG are calculated only when their inputs are comparable.
Score confidenceMissing and stale evidence reduces confidence and pulls the 0–100 research-priority score toward neutral.
Source standing2 cross-checked · 7 unverified · 1 withheld, of 10 graded companies.
How a second data feed is admitted, and what happens when it disagrees

A second feed is read only after its reported income is matched against the primary source on at least three overlapping periods. Where the two agree the figures fill silently. Where there is too little shared history to compare, the figures are still drawn — they are the only evidence there is — and marked ⚠ unverified everywhere they appear. Where the two are known to disagree, nothing from the second feed is drawn and the affected company is named under the chart it is missing from.

13 · questions investors ask, short speakable answers

Pharma - Others company comparison FAQs

These 22 answers restate the Pharma - Others comparison above in question form. Every one is computed from the same 10 companies and the same reported filings as the rankings and charts, current through Mar 2026. Price and relative-strength answers run through 2026-07-31. Nothing here is estimated, and none of it is a recommendation.

Is the Pharma - Others sector outperforming NIFTY 500?

Pharma - Others has outperformed NIFTY 500 by 16.3% over 52 weeks and 16.2% over 13 weeks. 8 of 10 covered companies beat NIFTY on Mansfield relative strength, while 5 of 10 beat the sector itself.

Which Pharma - Others company is largest by revenue?

Unichem Laboratories Ltd leads with revenue of ₹2,202 crore, based on 10 of 10 comparable companies through Mar 2026.

Which Pharma - Others company is growing fastest?

JOJO Ltd has the fastest current revenue growth at 100%, across 10 of 10 comparable companies.

Which Pharma - Others company has the strongest 4-Factor Sector Score?

JOJO Ltd ranks first at 66.2/100 with 69.3% evidence confidence. The score prioritizes research; it is not a buy recommendation.

How much history does this Pharma - Others comparison include?

The page compares up to 20 reported quarters per company for fundamentals, returns and valuation, ending Mar 2026. Missing observations remain blank rather than being estimated.

How is the 4-Factor Sector Score calculated?

The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral.

What is the Nifty Pharma - Others index?

The Nifty Pharma - Others index tracks India's listed Pharma - Others companies as a single basket. This page follows the same 10 companies and equal-weights them, so every company's weekly return counts once whatever it is worth, and the reading belongs to the Pharma - Others sector rather than to its largest constituent. Figures are as of Mar 2026.

Which are the best Pharma - Others stocks in India?

Ranked by this page's four-factor score, JOJO Ltd places first among 10 listed Pharma - Others companies, followed by Shukra Pharmaceuticals Ltd. That is a ranking of published data — earnings, quality, valuation and market behaviour as of Mar 2026 — and not a recommendation; Sector Alpha is not registered with SEBI as an investment adviser.

How many Pharma - Others stocks are listed in India?

This comparison covers 10 listed Pharma - Others companies in India, each above the size floor the site applies, with 20 quarters of reported figures per company where the filings exist. The full ranked list is on this page, as of Mar 2026.

Which Pharma - Others company is the biggest?

Unichem Laboratories Ltd is the largest, with trailing-twelve-month revenue of ₹2,202 crore, ahead of Sun Pharma Advanced Research Company Ltd at ₹1,879 crore. That covers 10 of 10 companies with comparable reporting through Mar 2026.

Which Pharma - Others company has the best profit margins?

Sun Pharma Advanced Research Company Ltd has the highest operating margin at 96%, from 10 of 10 comparable companies. Sun Pharma Advanced Research Company Ltd shows the biggest recent improvement, at +292 percentage points. A high margin matters most when it is holding or rising, not when it is peaking.

Which Pharma - Others company makes the most profit?

Sun Pharma Advanced Research Company Ltd earns the most, at ₹1,553 crore of trailing-twelve-month net profit, from 10 of 10 comparable companies. JOJO Ltd has the fastest profit growth at 100%, though growth off a small or recovering profit base overstates how much has actually changed.

Which Pharma - Others company earns the highest return on capital?

Sun Pharma Advanced Research Company Ltd leads on return on capital employed at 164%, across 10 of 10 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year.

Is the Pharma - Others sector beating the market?

Pharma - Others has outperformed NIFTY 500 by 16.3% over the last 52 weeks and 16.2% over 13 weeks, measured on an equal-weight index of its current members. Inside the sector, 8 of 10 covered companies are beating the market on their own. Sector strength does not transfer evenly to every stock in it.

Which Pharma - Others stock has the strongest price momentum?

Shukra Pharmaceuticals Ltd has the strongest relative strength against NIFTY 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all.

Which Pharma - Others company scores highest for research priority?

JOJO Ltd scores 66.2 out of 100 with 69.3% evidence confidence, from 30 points on growth and earnings, 13.6 on capital efficiency, 8.9 on valuation and 13.7 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research.

How many Pharma - Others companies does this comparison cover, and over what period?

It compares 10 listed companies over up to 20 reported quarters of fundamentals, ending Mar 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data.

What is the total market cap of the Pharma - Others sector?

The 10 Pharma - Others companies on this page carry ₹20,162 crore of combined market value. Sun Pharma Advanced Research Company Ltd is the largest at ₹6,692 crore, about 33% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-08-05.

What is the Pharma - Others sector's P/E ratio?

The median price-to-earnings ratio across the 10 Pharma - Others companies on this page is 22.9×, measured on the 9 that report a comparable figure. A sector-level history for this multiple is not held here, so this is a cross-section of today, not a comparison with the sector’s own past. Figures are as of 2026-08-05.

How is the Pharma - Others sector performing?

8 of the 10 covered Pharma - Others companies are beating NIFTY 500 on Mansfield relative strength. The sector itself is 16.3% ahead of NIFTY 500 over 52 weeks on an equal-weight index of its current members. Readings are as of 2026-08-05.

Why are some values on this page blank?

A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad.

Is this investment advice?

No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI